Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

On July 28, 2023 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297) (Press release, Natera, JUL 28, 2023, View Source [SID1234633488]). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive trial platform evaluating the utility of the Signatera molecular residual disease (MRD) test in patients with stage II-IV resectable colorectal cancer (CRC). CIRCULATE-Japan also includes the observational GALAXY study and the randomized phase III VEGA trial for ctDNA-guided treatment de-escalation. The company expects to share primary results from ALTAIR in mid-2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ALTAIR investigators have met their goal to enroll >240 patients who tested ctDNA-positive at any time within 2 years after surgery, but with no clinical or radiographic evidence of disease. ctDNA-positive patients are randomized to placebo or TAS-102 (trifluridine/tipiracil), a therapy commonly used for patients with metastatic CRC. The primary endpoint of the study is disease-free survival. ctDNA clearance is a secondary endpoint.

"In this study, we aim to establish the utility of Signatera in the adjuvant and surveillance settings by showing we can improve outcomes for patients with detectable ctDNA before it becomes evident on imaging," said Dr. Takayuki Yoshino of the National Cancer Center Hospital East, Kashiwa, Chiba, Japan and primary investigator of the CIRCULATE-Japan trial. "Randomized studies such as ALTAIR can help provide compelling evidence to support the use of ctDNA testing as a tool to guide treatment decisions in CRC."

Completion of enrollment to ALTAIR follows the release of multiple new datasets in 2023 highlighting the clinical utility of Signatera in CRC. In January, the results of >1,000 patients (>7,200 plasma time points) from GALAXY were published in Nature Medicine, demonstrating the ability of Signatera to identify patients with stage II-IV resectable CRC who are at an increased risk of recurrence and to predict who is most likely to benefit from adjuvant chemotherapy. Similar results were reported at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in June 2023 with additional data from an expanded cohort of >2,000 patients (>3,800 plasma time points) from the same study.

"The completion of enrollment to ALTAIR marks a significant milestone that will build on recent data from the GALAXY study and bring us one step closer to a future of ctDNA-guided cancer care," said Dr. Minetta Liu, chief medical officer of oncology at Natera. "We are proud to partner with our collaborators from CIRCULATE-Japan to accelerate precision medicine and transform care for patients with resectable CRC."

About Signatera

Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The test is available for both clinical and research use, and has been granted three Breakthrough Device Designations by the FDA for multiple cancer types and indications. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

On July 28, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported that the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company’s common stock to two newly hired employees (Press release, Ideaya Biosciences, JUL 28, 2023, View Source [SID1234633487]). The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals’ entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $21.07 per share, which is equal to the closing price of IDEAYA’s common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee’s continued service to IDEAYA on each vesting date.

AC Immune To Present At The BTIG Virtual Biotechnology Conference 2023

On July 28, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that Company Management will participate in a Fireside chat and one-on-one investor meetings during the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023 (Press release, AC Immune, JUL 28, 2023, View Source [SID1234633486]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the Fireside chat, Dr. Andrea Pfeifer, CEO of AC Immune SA, will discuss the Company’s clinical stage active immunotherapy pipeline to treat and, ultimately, prevent Alzheimer’s and other neurodegenerative diseases.

The live Fireside chat will take place on August 8, 2023, at 9:30 am (EDT) / 3:30 pm (CEST). AC Immune’s Management will take investor meetings on the same day. A replay will also be available through the BTIG Virtual Biotechnology Conference platform.

Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023

On July 28, 2023 Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that two abstracts were selected for presentation at the European Society for Medical Oncology Congress (ESMO) (Free ESMO Whitepaper) 2023 (Press release, Merus, JUL 28, 2023, View Source [SID1234633485]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will highlight updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), with an abstract and oral presentation concerning NRG1 fusion positive (NRG1+) non-small cell lung cancer (NSCLC) and an abstract presentation concerning NRG1+ pancreatic ductal adenocarcinoma (PDAC). The abstracts will be presented at the ESMO (Free ESMO Whitepaper) Congress 2023 taking place in Madrid, Spain October 20-24, 2023.

Merus is currently enrolling patients into the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.

Title: Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Speaker: Alison Schram
Mini Oral 1315MO
Lecture Time 9:35-9:40 CEST
Saturday, October 21

Title: Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Poster Session 1618P
Sunday, October 22

The full abstracts will be published online via the ESMO (Free ESMO Whitepaper) website at 00:05 CEST on Monday, October 16. They will be available concurrently on the Merus website.

About the eNRGy Clinical Trial
Merus is currently enrolling patients in the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer. The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and other NRG1+ cancer. Further details, including current trial sites, can be found at www.ClinicalTrials.gov and Merus’ trial website at www.nrg1.com or by calling 1-833-NRG-1234.

About Zeno
Zeno is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics that utilizes the Merus Dock & Block mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 fusions (NRG1+ cancer). Through its unique mechanism of binding to HER2 and potently blocking the interaction of HER3 with its ligand NRG1 or NRG1-fusion proteins, Zeno has the potential to be particularly effective against NRG1+ cancer. In preclinical studies, Zeno potently inhibits HER2/HER3 heterodimer formation thereby inhibiting oncogenic signaling pathways, leading to inhibition of tumor cell proliferation, and blocking tumor cell survival.

Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised

On July 28, 2023 Sanofi reported Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised (Press release, Sanofi, JUL 28, 2023, View Source [SID1234633484]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q2 2023 sales growth of 3.3% at CER and business EPS(1) growth of 8.1% at CER

Specialty Care grew 11.8% driven by Dupixent (€2,562 million, +34.2%) and Nexviazyme (€103 million, +146.5%) more than offsetting anticipated impact of Aubagio generic competition in the U.S.
Vaccines up 9.1% due to strong PPH vaccines sales in Rest of World region and COVID vaccine supply in Europe
General Medicines core assets grew 2.4%, non-core assets lower mainly due to Lantus (€353 million, -36.5%)
CHC sales growth continued (+0.7%) despite unfavorable effect from inventory build in the prior quarter
Business EPS(1) of €1.74 up 0.6% on a reported basis and 8.1% at CER
IFRS EPS of €1.15 (up 22.3%)
Key R&D milestones and regulatory achievements in Q2

Nirsevimab unanimous FDA AdCom vote for prevention of RSV lower respiratory tract disease in infants
Dupixent BOREAS Phase 3 COPD results presented at ATS and published in the New England Journal of Medicine
Itepekimab in COPD passed a recent interim futility analysis of the Phase 3 AERIFY studies
Amlitelimab positive Phase 2b data support potential for transformational target profile in Atopic Dermatitis
Frexalimab Phase 2b primary endpoint met demonstrating significantly reduced disease activity in MS
Vaccines pipeline moving at pace with 12 innovative assets with new data highlighted at a recent investor event
Progress on Corporate Social Responsibility strategy in Q2

Inclusivity targets implemented across clinical trial; 45% of U.S. trials achieved at least 1 target
B Corp Certification granted to CHC North America in recognition of environmental and social achievements
Full-year 2023 business EPS guidance revised upward

Sanofi now expects 2023 business EPS(1) to grow mid single-digit(2) at CER, barring unforeseen major adverse events. Applying average July 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -6.5% to -7.5%. This upgrade includes approximately €400 million of expected one-off COVID vaccine revenues in the second half of the year.

Paul Hudson, Sanofi Chief Executive Officer, commented:

"We have delivered yet another quarter of growth, with Specialty Care and Vaccines as the main drivers. As we move into the second half our Play to Win strategy, we are particularly enthusiastic about the strong flow of positive R&D data readouts and regulatory achievements of this second quarter, highlighting the significant growth potential of our innovative pipeline assets. With the FDA approval of Beyfortus for the prevention of RSV in all infants in July, the landmark Phase 3 data in COPD with Dupixent, and the important clinical milestones with amlitelimab and frexalimab which support our decision to initiate pivotal trials, we expect to add multiple innovative medicines to our existing growth drivers over the coming years. As we enter the second half of 2023, we are executing on our new launches and we are encouraged by the early launch indicators of ALTUVIIIOTM and TZIELDTM, while navigating the anticipated impact from generic competition on Aubagio. Our strong results in the first six months make us confident in our outlook for the remainder of the year and as a consequence we are raising our full-year 2023 EPS guidance to mid single-digit growth."

Q2 2023 Change Change
at CER H1 2023 Change Change
at CER
IFRS net sales reported €9,965m -1.5% +3.3% €20,187m +2.0% +4.4%
IFRS net income reported €1,435m +22.1% _ €3,430m +7.7% —
IFRS EPS reported €1.15 +22.3% _ €2.74 +7.5% —
Free cash flow(3) €1,592m +3.7% _ €3,129m -3.5% —
Business operating income €2,726m -1.0% +6.6% €6,059m +4.1% +8.0%
Business net income(1) €2,177m +0.3% +8.0% €4,876m +6.1% +10.0%
Business EPS(1) €1.74 +0.6% +8.1% €3.90 +6.0% +9.8%

Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q2 2023 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2022 business EPS was €8.26; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 9).